ECSP15022442A - Producto de comicronización que comprende acetato de ulipristal - Google Patents

Producto de comicronización que comprende acetato de ulipristal

Info

Publication number
ECSP15022442A
ECSP15022442A ECIEPI201522442A ECPI201522442A ECSP15022442A EC SP15022442 A ECSP15022442 A EC SP15022442A EC IEPI201522442 A ECIEPI201522442 A EC IEPI201522442A EC PI201522442 A ECPI201522442 A EC PI201522442A EC SP15022442 A ECSP15022442 A EC SP15022442A
Authority
EC
Ecuador
Prior art keywords
ulipristal acetate
product including
comicronization
comicronization product
product
Prior art date
Application number
ECIEPI201522442A
Other languages
English (en)
Inventor
Pierre-Yves Juvin
Florian Battung
Aude Colin
Jérôme Hecq
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of ECSP15022442A publication Critical patent/ECSP15022442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Thyristors (AREA)
  • Circuit Arrangements For Discharge Lamps (AREA)
  • Emergency Protection Circuit Devices (AREA)

Abstract

La presente invención tiene por objeto un producto de comicronización que comprende una sustancia activa elegida entre el grupo constituido por el acetato de ulipristal, un metabolito del acetato de ulipristal y sus mezclas, y un tensioactivo sólido aceptable desde el punto de vista farmacéutico. La invención se refiere también a una composición farmacéutica que comprende dicho producto de comicronización y sus utilizaciones terapéuticas.
ECIEPI201522442A 2012-11-08 2015-06-05 Producto de comicronización que comprende acetato de ulipristal ECSP15022442A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1260603A FR2997627B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant de l'ulipristal acetate

Publications (1)

Publication Number Publication Date
ECSP15022442A true ECSP15022442A (es) 2016-01-29

Family

ID=47878175

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201522442A ECSP15022442A (es) 2012-11-08 2015-06-05 Producto de comicronización que comprende acetato de ulipristal

Country Status (30)

Country Link
US (2) US9610293B2 (es)
EP (1) EP2916871B1 (es)
JP (1) JP2015536968A (es)
KR (1) KR20150093170A (es)
CN (1) CN104902928B (es)
AR (1) AR093402A1 (es)
AU (1) AU2013343320B2 (es)
BR (1) BR112015010271B1 (es)
CA (1) CA2890272A1 (es)
CR (1) CR20150297A (es)
CY (1) CY1119542T1 (es)
DK (1) DK2916871T3 (es)
EA (1) EA027641B1 (es)
EC (1) ECSP15022442A (es)
ES (1) ES2606307T3 (es)
FR (1) FR2997627B1 (es)
GE (1) GEP201706637B (es)
HR (1) HRP20161624T1 (es)
HU (1) HUE031911T2 (es)
LT (1) LT2916871T (es)
MD (1) MD4563C1 (es)
MX (1) MX363699B (es)
PL (1) PL2916871T3 (es)
PT (1) PT2916871T (es)
RS (1) RS55429B1 (es)
SI (1) SI2916871T1 (es)
SM (1) SMT201600445B (es)
TW (1) TWI617325B (es)
UA (1) UA117465C2 (es)
WO (1) WO2014072646A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
CN103923154B (zh) * 2013-01-16 2017-09-26 杭州容立医药科技有限公司 醋酸乌利司他的共晶及制备方法
CN105663140A (zh) * 2014-11-21 2016-06-15 四川海思科制药有限公司 一种含醋酸乌利司他的药物组合物及其制备方法
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
CN105919150A (zh) * 2016-05-12 2016-09-07 高洁珺 一种代替压片工艺中化工添加剂的方法
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
ATE497745T1 (de) 2004-07-09 2011-02-15 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
WO2008037044A1 (en) 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
JP5649305B2 (ja) 2006-12-20 2015-01-07 テバ ウィメンズ ヘルス インコーポレイテッド プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法
EP2094275A2 (en) * 2006-12-28 2009-09-02 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CA2757496A1 (en) 2009-04-14 2010-10-21 Andre Ulmann Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate

Also Published As

Publication number Publication date
PL2916871T3 (pl) 2017-02-28
US20170157146A1 (en) 2017-06-08
EP2916871A1 (fr) 2015-09-16
KR20150093170A (ko) 2015-08-17
MX2015005762A (es) 2016-02-11
CA2890272A1 (fr) 2014-05-15
CN104902928B (zh) 2018-10-23
PT2916871T (pt) 2016-12-15
MX363699B (es) 2019-03-28
TWI617325B (zh) 2018-03-11
US9610293B2 (en) 2017-04-04
CN104902928A (zh) 2015-09-09
FR2997627A1 (fr) 2014-05-09
HUE031911T2 (en) 2017-08-28
AR093402A1 (es) 2015-06-03
EP2916871B1 (fr) 2016-09-14
UA117465C2 (uk) 2018-08-10
HRP20161624T1 (hr) 2017-01-27
JP2015536968A (ja) 2015-12-24
CR20150297A (es) 2015-08-14
SI2916871T1 (sl) 2017-03-31
RS55429B1 (sr) 2017-04-28
US20150290218A1 (en) 2015-10-15
BR112015010271B1 (pt) 2020-04-22
CY1119542T1 (el) 2018-03-07
EA201500513A1 (ru) 2015-08-31
EA027641B1 (ru) 2017-08-31
TW201427718A (zh) 2014-07-16
DK2916871T3 (da) 2017-01-02
WO2014072646A1 (fr) 2014-05-15
GEP201706637B (en) 2017-03-10
SMT201600445B (it) 2017-01-10
MD20150053A2 (ro) 2015-10-31
ES2606307T3 (es) 2017-03-23
LT2916871T (lt) 2016-12-27
BR112015010271A2 (pt) 2017-07-11
MD4563C1 (ro) 2018-12-31
FR2997627B1 (fr) 2015-01-16
AU2013343320A1 (en) 2015-06-04
BR112015010271A8 (pt) 2019-10-01
MD4563B1 (ro) 2018-05-31
AU2013343320B2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
PE20140255A1 (es) Tableta dispersable en forma oral
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
HK1221418A1 (zh) 释放修饰药物的水凝胶-连接的前药
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
IN2014MN02236A (es)
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
MX2017008983A (es) Composición farmaceútica de sulfonamida.
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
IN2014DN07897A (es)
EA201400808A1 (ru) Стабилизированные фармацевтические составы сильнодействующего ингибитора вируса гепатита с
ES2523458A1 (es) Composición farmacéutica o cosmética para la regeneración y cicatrización de la piel
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos